Skip to main content

Table 2 Overall cognitive impairment according to APOE4 status and interactions with chemotherapy and endocrine therapy

From: Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study

 

Baseline

Year-1

Year-2

Year-4

 

OR

95% CI

p

OR

95% CI

p

OR

95% CI

p

OR

95% CI

p

APOE4

1.1

0.55–2.13

0.77

0.89

0.37–2.02

0.78

1.2

0.49–2.78

0.69

1.13

0.41–2.97

0.8

APOE4 × CT

1.24

0.32–4.84

0.75

1.5

0.27–8.69

0.64

0.72

0.12–4.13

0.71

2.71

0.37–21.1

0.33

APOE4 × ET

0.86

0.16–5.11

0.88

1.18

0.15–10.6

0.88

1.4

0.12–19.5

0.8

0.11

0.01–1.22

0.07

  1. Each line is the result of a different logistic model
  2. APOE4, Apolipoprotein Ɛ4 isoform status; CT, chemotherapy status; ET, endocrine therapy status; OR, odds ratio; p, p value; 95% CI, 95% confidence interval
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us